X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

PBYI

Closed

Puma Biotechnology Inc

3.59
+0.16 (+4.66%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.43
Day's Range: 3.44 - 3.65
Send
When Written:
 
2.93
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative treatments for cancer. The company's lead product, Neratinib, is a tyrosine kinase inhibitor that is approved for the treatment of HER2-positive breast cancer. Puma Biotechnology's pipeline includes other targeted therapies for cancer, including PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer and HER2-mutated solid tumors, and PB357, a small molecule inhibitor of the IRAK4 kinase for the treatment of hematologic malignancies and solid tumors. The company was founded in 2010 and is headquartered in Los Angeles, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X